Member Info for BittenTwiceShy

Rather than paying dividends too early, I would rather they carry on building up the portfolio at this relatively early stage. The board have shown themselves to be excellent deal makers and they should give themselves every opportunity to continue doing so.

It's all very dispiriting. I've been here since the Camco days. When Camco was palmed off and the company switched into VRFBs I thought it was a good move at the time. Let's just hope the company's still around when/if VRFBs have their day.

It seems to be general risk aversion across the whole market as inflation takes hold. It's difficult for the market to predict the future increases in research costs while this climate persists. Gelesis's rocky start to public trading hasn't helped either.

Sentiment will change dramatically as Puretech's trial programs mature and their founded entities grow their markets.

Everything is coming into place very quickly for this company. Cash is king, and Trident are starting to generate a lot of it!

Agreed. If (big if) the pandemic starts to subside it should be a much better climate for the IPO - and for medical cannabis.

Have you heard any more about the SW Brands IPO? There was lots of talk in the Summer but it seems to have gone a bit quiet.

Great RNS today about a $30 million order for Plenity. Puretech still own 19.2% plus royalties so, depending on profit margins, this order must be worth a few million to Puretech. There is huge demand out there, approximately 150 million Americans are overweight!

I'm invested here as an inflation hedge and for the future dividend stream. The first part is certainly playing out as I hoped.

Entered the FTSE 250 today. I'm not sure if many tracker funds follow the whole 250 but it's definitely going to help with visibility and awareness.
GLA.

He said he wouldn't accept £50 million for the company.

Ed said that it would be illegal for him to buy shares at present due to his involvement with Leap. Not sure about Alfredo, is there anything stopping him buying?

Yes, thanks for the link Legsofman.
Kaye184, could you elaborate on what you think is wrong? From what I could make of it, he was saying that the the dilutive effect of the new share issuance will be more than offset by high quality long term rental income from the new acquisitions. What's wrong with that?

Stunning set of results, more growth to come, constrained competition, what's not to like?

Reading the original prospective from February 2021, it should be 1 new share at £1.11 for every 5 held.

Thanks legsofman, do you have a link to the article?

What's anyone's views on this? On the face of it, it looks accretive, especially the new warehouse build in the Rhine-Rhur region. It will be interesting to see if existing private shareholders are given the opportunity to purchase the new shares, although I suspect it will be Institutional Investors only.

This type of deal is exactly why I invested in Trident. It's a classic win-win: the miner gets access to the finance they need and only pay it back when they start generating revenue. For Trident, the risk is as low as it can possibly be in mining: a mothballed mine being restarted, large proven reserves and potentially enormous unproven reserves. Well done to the whole Trident team!

Thanks for the update Rivaldo, sounds positive on all fronts. I meant to attend this morning but couldn't make it in the end.

I've also read through the results and it I personally can't see any problems, steady progress on all fronts.
I particularly liked Dr Krop's statement:
"I am thrilled to join the leadership team at PureTech during such an exciting time in the Company's growth and clinical development. PureTech's research and development model is a truly unique approach that has fostered a broad wealth of expertise within the Company that now powers the team's innovative development efforts across multiple therapeutic candidates. I look forward to helping drive PureTech's mission and advancing an incredibly promising pipeline of investigational therapies for patients in need."
I'm happy to hold and top up on any dips.

One of the issues may be that the market thinks that the treatments are TOO good. Pharmaceutical companies don't make money by eradicating illnesses, they make money by managing the symptoms on an ongoing basis. This may sound cynical but it's the way things are set up unfortunately. Governments don't take into account the cost/benefits of drugs, and private pharmaceutical companies have actually gone bankrupt by spending large amounts on research which eventually cures a disease. Why they can't set up a system which rewards companies properly for eradicating diseases is beyond me.
The risk in Puretech's case is very low, but it may be having a bearing on the price.